<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>New <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> drugs designed for enhancing GABAergic inhibition, such as vigabatrin (VGB) may be effective in <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome (AS)</z:e>, because associated <z:mp ids='MP_0000947'>convulsions</z:mp> could be related to a reduced <z:chebi fb="3" ids="16865">GABA</z:chebi>-receptor density or receptor abnormality </plain></SENT>
<SENT sid="1" pm="."><plain>From our preliminary experiences in four children with AS treated with VGB, we conclude that it may induce and increase <z:hpo ids='HP_0001250'>seizures</z:hpo> in patients with AS </plain></SENT>
</text></document>